公开(公告)号：US20230181641A1

公开(公告)日：2023-06-15

申请号：US17924635

申请日：2021-05-12

申请人： Juno Therapeutics, Inc.

发明人： Nathan YEE ,  Ryan LARSON ,  Calvin CHAN ,  Sara COOPER ,  Jeffrey TEOH ,  Daniel COSSETTE ,  Kohana LEUBA

IPC分类号： A61K35/17 ,  C12N5/0783 ,  C07K14/725 ,  C07K14/705 ,  C07K14/715 ,  A61K38/17 ,  A61P35/00

CPC分类号： A61K35/17 ,  C12N5/0636 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/7151 ,  A61K38/1774 ,  A61P35/00 ,  C12N2500/32 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/515 ,  C12N2501/51

摘要： Provided herein are methods of producing engineered T cell compositions enriched for CD57 negative and/or CD27 positive T cells, such as from a plurality of donors. In some embodiments, the T cells are engineered with a recombinant receptor, such as a chimeric antigen receptor (CAR). Also provided herein are engineered T cell compositions containing T cells enriched for CD57 negative and/or CD27 positive T cells derived from a plurality of different donors, including compositions in which the T cells are engineered with or express a recombinant receptor (e.g. CAR). Also provided are methods of using the engineered T cell compositions in adoptive therapy, including in connection for cancer immunotherapy, such as for allogeneic therapies or for administration to one or more subjects in which the T cells are not derived from the subject(s) to whom the compositions are administered.

公开(公告)号：US20240151713A1

公开(公告)日：2024-05-09

申请号：US18347434

申请日：2023-07-05

申请人： Juno Therapeutics, Inc.

发明人： Nathan YEE ,  Chris Glen RAMSBORG ,  Tina ALBERTSON ,  Ryan LARSON ,  He LI

IPC分类号： G01N33/50 ,  A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  G01N33/574

CPC分类号： G01N33/5091 ,  A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/2803 ,  C12N5/0636 ,  G01N33/5047 ,  G01N33/57407 ,  C07K2319/02

摘要： Provided are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a marker by assaying a biological sample from a subject that is a candidate for treatment, optionally with a cell therapy, to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS. In some embodiments, the methods and articles of manufacture further includes a regent for assaying the biological sample and instructions for determining the percentage or number of cells positive for the marker in the biological sample.